Literature DB >> 33119072

Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans.

Maria Rebelo1, Rebecca Pawliw1, Jeremy Gower1, Lachlan Webb1, Hayley Mitchell1, Zuleima Pava1, Rebecca E Watts1, Miles P Davenport2, James S McCarthy1, David S Khoury2.   

Abstract

BACKGROUND: Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable.
METHODS: Plasmodium falciparum-infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects.
RESULTS: We showed that in artemisinin-sensitive infection, viable parasites declined to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline.
CONCLUSIONS: These results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Malaria; antimalarial; drug development; efficacy; parasite clearance; viability

Mesh:

Substances:

Year:  2021        PMID: 33119072     DOI: 10.1093/infdis/jiaa678

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  3 in total

1.  Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment.

Authors:  Georges F R Radohery; Annabelle Walz; Christin Gumpp; Mohammed H Cherkaoui-Rbati; Nathalie Gobeau; Jeremy Gower; Miles P Davenport; Matthias Rottmann; James S McCarthy; Jörg J Möhrle; Maria Rebelo; Claudia Demarta-Gatsi; David S Khoury
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

2.  Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate?

Authors:  Nicholas J White; James A Watson
Journal:  J Infect Dis       Date:  2021-08-16       Impact factor: 7.759

3.  Similarly efficacious anti-malarial drugs SJ733 and pyronaridine differ in their ability to remove circulating parasites in mice.

Authors:  Arya SheelaNair; Aleksandra S Romanczuk; Rosemary A Aogo; Miles P Davenport; Ashraful Haque; David S Khoury; Rohit Nemai Haldar; Lianne I M Lansink; Deborah Cromer; Yandira G Salinas; R Kiplin Guy; James S McCarthy
Journal:  Malar J       Date:  2022-02-16       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.